XENETIC BIOSCIENCES INC (XBIO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.67+0.86%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · XBIO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -77.5% |
| Our one-year growth estimate | diamond | -18.2% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 59.4 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
XBIO — officer change
Dated 2026-04-24
James Parslow: Compensatory arrangement and equity grant to an existing officer.
Why it matters: Updates might show changes in company direction or new partnerships. This can affect investor feelings and stock performance.
Watch forAnnouncement of a new partnership or acquisition from the review will be made.
Also watch forNo updates or a choice not to seek new strategies will be made.
Why it matters: Positive results would support the potential of DNase I as a therapy for cancer. This could attract more partnerships and funding.
Supportive ifNew data shows DNase I makes CAR T-cell therapy work better.
Worry ifNegative results from the study show DNase I may not work well.
Why it matters: Revenue growth trends indicate the company's market position and future potential. A drop could signal trouble.
Worry ifRevenue growth drops below the median for the sector.
Less concerning ifRevenue growth remains above the median for the sector.
Why it matters: Cash levels are key for funding operations and clinical trials.
Worry ifCash reserves remain stable or increase above $7.5 million in the next quarter.
Less concerning ifCash reserves drop below $6 million, which may lead to liquidity problems.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$226 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $719 loss on $10,000 · 7.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,050 loss on $10,000 · 80.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Good data would show that DNase I helps cancer treatments.
Supportive ifPositive early data for DNase I is shared at big cancer meetings.
Worry ifNegative or unclear data from DNase I studies is shown at conferences.
Why it matters: The health care sector is slowing. If it improves, XBIO may benefit. Investors should monitor this closely.
Watch forHealth care sector revenue growth speeds up above 10%.
Also watch forHealth care sector revenue growth slows down below 5%.
Why it matters: Steady or rising royalty income helps pay for development work.
Supportive ifRoyalty revenue for the next quarter exceeds $0.7 million.
Worry ifRoyalty revenue declines below $0.7 million in the next quarter.
Why it matters: Advancing the DNase I platform is key for future growth and potential revenue.
Supportive ifA new clinical trial is announced or positive results come from ongoing studies.
Worry ifDelay or cancellation of planned clinical trials for the DNase I platform.